Evidence-Based Multidisciplinary Hemophilia Management in Treatment Centers and Underserved Community Referral Networks

Learn strategies to better individualize prophylaxis therapy for patients with hemophilia and stay up to date on advancements in factor replacement therapies, hemostatic rebalancing agents, and gene therapy through an on-demand webcast, downloadable slides, and an expert-written ClinicalThought commentary. 

Share

Program Content

Activities

Latest in Hemophilia Management
Evidence-Based Multidisciplinary Hemophilia Management in Treatment Centers and Underserved Community Referral Networks
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 06, 2024

Expires: September 05, 2025

Activities

Hemophilia Management in Underserved Communities
Evidence-Based Multidisciplinary Hemophilia Management in Treatment Centers and Underserved Community Referral Networks
Video
Congratulations: You achieved a completion on 04/09/2022

Released: November 11, 2024

Expires: April 17, 2025

Faculty

cover img faculity

Fernando F Corrales-Medina, MD, FAAP

Associate Professor of Clinical Pediatrics
Medical Director, Pediatric Hemophilia Program
Director, Pediatric Hematology-Oncology Fellowship Program
University of Miami Hemophilia Treatment Center
Division of Pediatric Hematology-Oncology
University of Miami Miller School of Medicine
Miami, Florida

cover img faculity

Mark T Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

cover img faculity

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Novo Nordisk and Sanofi.

Novo Nordisk

Sanofi